An Uncontrolled Phase II Study Evaluating the Efficacy and Safety of Intravenous BAY 59-8862 [ortataxel] in Patients With Taxane-Resistant Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 26 May 2009
At a glance
- Drugs Ortataxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Bayer
- 26 May 2009 Actual end date (Feb 2004) added as reported by ClinicalTrials.gov.
- 19 May 2008 Results reported at ASCO 2008.
- 19 May 2008 New trial record.